The "Sweet Spot" in Type 2 Diabetes Management

Slideshow

The new "sweet spot" in diabetes management is the interdisciplinary approach that is essential to treating all aspects of the disease. New diabetes medications also hit that spot.

Recent Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
Investigational Drug Reduces Lp(a) in High-Risk Adults: Daily Dose / image credit: ©New Africa/AdobeStock

Investigational Drug Reduces Lp(a) in High-Risk Adults: Daily Dose

Sydney Jennings
December 4th 2024
Article

Your daily dose of the clinical news you may have missed.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Sydney Jennings
August 30th 2023
Podcast

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

GLP-1RAs, SGLT2is Cut Risk of Future MI, Stroke in Survivors: Daily Dose / image credit: ©New Africa/AdobeStock

GLP-1RAs, SGLT2is Cut Risk of Future MI, Stroke in Survivors: Daily Dose

Sydney Jennings
November 25th 2024
Article

Your daily dose of the clinical news you may have missed.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

Sydney Jennings
June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Among Stroke Survivors, GLP-1RAs, SGLT2is May Reduce Risk of Future MI, Recurrent Stroke / image credit American Heart Association

Among Stroke Survivors, GLP-1RAs, SGLT2is May Reduce Risk of Future MI, Recurrent Stroke

Grace Halsey
November 11th 2024
Article

AHA 2024. Study authors reported a 74% lower risk of death and an 84% lower risk of MI among participants taking either a GLP-1RA or an SGLT2i.

New Phase 3 Trials Investigate Survodutide as a Promising Treatment for Obesity / Image credit: ©missbobbit/AdobeStock

New Phase 3 Trials Investigate Survodutide as a Promising Treatment for Obesity

Sydney Jennings
November 6th 2024
Article

SYNCHRONIZE-1 and -2 will provide "robust evidence" on the safety, efficacy, and tolerability of survodutide in adults with obesity with or without T2D.

© 2024 MJH Life Sciences

All rights reserved.